Cargando…
What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?
The first SARS-CoV-2 vaccine(s) will likely be licensed based on neutralizing antibodies in Phase 2 trials, but there are significant concerns about using antibody response in coronavirus infections as a sole metric of protective immunity. Antibody response is often a poor marker of prior coronaviru...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452821/ https://www.ncbi.nlm.nih.gov/pubmed/32875286 http://dx.doi.org/10.1016/j.jvacx.2020.100076 |